GlobeNewswire Inc.··Belite Bio, IncBelite Bio Pursues FDA Approval for Tinlarebant, Potential First Stargardt Disease Treatment
Belite Bio begins rolling NDA submission to FDA for tinlarebant, a potential breakthrough oral therapy for rare Stargardt disease, targeting 2027 commercialization.
BLTEFDA approvalrare disease